ViroMed Co., Ltd.

Viromed Co. Ltd. (Viromed) is a Korea based biotechnology company. The company is principally engaged in the research and development of gene therapy and recombinant proteins for the treatment of human diseases including cardiovascular diseases, chemotherapy and immune related diseases. It focuses on two areas, protein-based biopharmaceuticals and phytotherapeutics. The company uses gene therapy to treat coronary artery disease (CAD), periphery artery disease and the diabetic peripheral neuropathy. It has also developed cell based gene therapy for the treatment of chronic granulomatous disease (CGD). The pipeline products of the company include VM202, VM501, PG102, PG201 and VM206. It has alliances with biotechnology and research organizations across the globe including the US, China, Korea, Europe and Japan. Viromed is headquartered in Seoul, Korea.

Street: 
5th Floor, Bldg
City: 
Gwanak-gu
Postcode: 
151-747
Federal State : 
Republic of Korea
WebSite: 
www.viromed.co.kr
Fax: 
82-2-21027280

Company Index Score

Current Index Score Historical Index Score
  • ViroMed Co., Ltd. currently scores 50 % in the index.
  • ViroMed Co., Ltd. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • ViroMed Co., Ltd. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets